Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma
Abstract Introduction Systemic therapy for advanced renal cell carcinoma (aRCC) has become increasingly diverse. In the 1st-line setting, various combination therapies are available, with little comparative data on the efficacy of the therapies. The aim of this study was to compare the current 1st-l...
Saved in:
| Main Authors: | Maximilian Haack, Stephanie Neuberger, Jan Hendrik Boerner, Stefanie Ziewers, Gregor Duwe, Robert Dotzauer, Axel Haferkamp, Rene Mager |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02131-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3)
by: Puco K, et al.
Published: (2025-01-01) -
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment—real world comparative effectiveness from German claims data
by: Axel Dignass, et al.
Published: (2025-06-01) -
Real-world first-line serplulimab therapy for advanced esophageal cancer: effectiveness, safety, and clinical implications
by: Fei Yan, et al.
Published: (2025-08-01) -
Real‐world experience of adjuvant immunotherapy for stages III–IV melanoma: A monocentric observational study
by: Manon Blaise, et al.
Published: (2025-06-01) -
Real-World, Observational, Retrospective Study to Evaluate the Effectiveness and Safety of Treatment with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
by: Angélica Richart Csipak, et al.
Published: (2024-11-01)